

Enfusion Integrata high profile launch

Background

- High profile Boston based multi-strategy and long/short equity manager launched in Q4 2013
- Quickly grew to \$1.2 billion from \$500 million at launch
- Trades globally across equities, derivatives and fixed income
- Low trading volume with concentrated positions
- Multiple prime brokers
- Systems: Eze Castle and Enfusion Integrata

Objectives

- Purchase technology license but outsource the maintenance and services to Viteos, excluding OMS
- Achieve institutional grade platform by leveraging Viteos reconciliation technology alongside external applications
- Enable scalability without the need to hire additional staff
- Partner with a strategic solutions provider who can support all asset classes and strategies

Client Snapshot:

AUM: \$1.2 billion

Location: Boston, MA

Strategies: Multi-strategy & Long/short Equity

Asset classes: Equities, Derivatives, Fixed Income

Trading region: Global

Prime brokers: Goldman Sachs, Morgan Stanley, Credit Suisse

Fund administrator: Morgan Stanley

Solution

- Implement and maintain Enfusion Integrata
- Daily reconciliations covering prime brokers, counterparties and internal systems
- Manage complete post-trade life cycle covering trade booking, reference master setup/maintenance, pricing, corporate actions and non-trade activity processing within Enfusion
- Facilitate intra-day trade feed from Eze Castle to Enfusion Integrata, and address exceptions
- Compare intra-day profit/loss between Eze Castle and Enfusion Integrata
- Produce end-of-day unreconciled profit/loss reporting
- Produce daily reporting covering profit/loss and exposures
- Prepare independent NAV calculations and economic allocations, and reconcile to administrator